Rationally Designed Peptide Immunotherapy for Peanut Allergy: Bringing Antigen-Specific Immune Tolerance into Late-Stage Clinical Reality

• Exploring Aravax’s peptide-based immunotherapy that is designed to induce antigenspecific immune tolerance by precisely targeting T-cells
• Delving into the translational strategy that has led to late phase II clinical trials

NEW DATA

Speakers:

Sara Prickett

Chief Scientific Officer

Aravax